Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
Handling and Storage Recommendations Store at 20C immediately upon receipt
The tailwinds are real, the TAM is enormous, and the entry barriers are rising
The first available amylin agonist was pramlintide, which is already approved for treatment of type 1 and type 2 diabetes in conjunction with insulin [4]
In the global phase 3 Semaglutide Treatment Effect in People with Obesity (STEP) program, no difference was found between semaglutide and placebo regarding psychiatric adverse effects (3)
Enrolling Metabolic Dysfunction-Associated Steatotic Liver Disease Drug: Tirzepatide Drug: Placebo A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3 Active, not recruiting NASH - Nonalcoholic Steatohepatitis Drug: Placebo Drug: IVA337 A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat
US$ 28.64
US$ 23.96
US$ 21.02
US$ 29.47
US$ 20.66
